Drugs that contain Peginesatide Acetate
1. Omontys patents expiration
Can you believe OMONTYS received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(23 days from now) | |
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
More Information on Dosage
OMONTYS family patents
2. Omontys Preservative Free patents expiration
Can you believe OMONTYS PRESERVATIVE FREE received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7528104 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| US7919118 | TAKEDA PHARMS USA | Spacer moiety for poly (ethylene glycol) modified peptide based compounds |
May, 2024
(23 days from now) | |
| US7414105 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| US7084245 | TAKEDA PHARMS USA | Peptides that bind to the erythropoietin receptor |
May, 2024
(23 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7550433 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
| US7919461 | TAKEDA PHARMS USA | Erythropoietin receptor peptide formulations and uses |
Jun, 2026
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 27, 2017 |
NCE-1 date: 27 March, 2016
Market Authorisation Date: 27 March, 2012
Treatment: Treatment of anemia due to chronic kidney disease
Dosage: SOLUTION;INTRAVENOUS, SUBCUTANEOUS
More Information on Dosage
OMONTYS PRESERVATIVE FREE family patents